BIOCRYST PHARMACEUTICALS, INC. Deferred Tax Assets, Operating Loss Carryforwards, Domestic
BIOCRYST PHARMACEUTICALS, INC. (BCRX) had Deferred Tax Assets, Operating Loss Carryforwards, Domestic of $82.05 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic · last filed 2026-02-26
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $82.05M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $105.86M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $108.75M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $101.60M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, Domestic |
|---|---|
| 2025-12-31 | $82.05M 10-K · filed 2026-02-26 |
| 2024-12-31 | $105.86M 10-K · filed 2026-02-26 |
| 2023-12-31 | $108.75M 10-K · filed 2025-02-25 |
| 2022-12-31 | $101.60M 10-K · filed 2024-02-27 |
| 2021-12-31 | $113.65M 10-K · filed 2023-02-27 |
| 2020-12-31 | $159.94M 10-K · filed 2022-02-28 |
| 2019-12-31 | $155.19M 10-K · filed 2021-03-01 |
| 2018-12-31 | $137.23M 10-K · filed 2020-03-13 |
| 2017-12-31 | $117.79M 10-K · filed 2019-03-14 |
| 2016-12-31 | $158.62M 10-K · filed 2018-03-12 |
| 2015-12-31 | $142.84M 10-K · filed 2017-02-27 |
| 2014-12-31 | $135.92M 10-K · filed 2016-02-26 |
| 2013-12-31 | $119.94M 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |